Why ARTMS

Our Vision is to lead the enhancement of human health through medical isotope innovation by creating the tools, technologies and products that solidify medical isotope supply and empower the Nuclear Medicine community

Empowerment

Sustainability

Innovation

Solving a Problem

ARTMS’ technology was founded by a group of TRIUMF scientists, including ARTMS’ current Chief Technology Officer, Dr. Paul Schaffer in 2013 to tackle projected Technetium-99m shortages after the decommissioning of the reactor at Chalk River. Once the goal of cyclotron produced Technetium-99m was achieved, ARTMS continued to innovate by developing new solid targets, streamlined processes and standard purification protocols. Eventually ARTMS. was formed and operated as a stand-alone entity from 2016 to 2024 when the company was acquired by Telix Pharmaceuticals.

Expanding Partnerships & Regulatory Approval

ARTMS secured several rounds of funding between 2016 and 2020, and expanded from Technetium production to PET isotopes such as Gallium-68. The latest round of funding in May 2020 allowed ARTMS to focus on partners that need to produce large volumes of PET isotopes such as Gallium-68 and Zirconium-89 used in the preparation of radiopharmaceuticals for molecular imaging studies, along with securing regulatory approvals for this type of production and usage.

Revolutionizing Nuclear Medicine

ARTMS has forever changed the way isotopes are supplied to clinicians and patients. ARTMS’ continued innovation and partnership will help ensure that tens of thousands of patients will receive the appropriate diagnostic scan at the proper time.

The ARTMS Leadership Team

Doug Gentilcore

(Chief Executive Officer)

Doug Gentilcore is the Chief Executive Officer of ARTMS. Gentilcore has over 15 years of senior level sales in global radiopharmaceutical and imaging markets. Gentilcore was President of Implerem, a consulting firm focused on strategic and commercial solutions for the nuclear medicine industry. Prior to Implerem, he was the VP of Global Sales and Business Operations at Jubilant Radiopharma where he grew the sales/business operations team from a staff of 8 to over 70. Gentilcore has also held roles of increasing responsibility at Purview-Force 3, GE Healthcare, and Pfizer. Gentilcore has a BA in Business Economics from Randolph-Macon College.

Dr. Paul Schaffer

(Chief Technical Officer)

Dr. Paul Schaffer is CTO of ARTMS and Head of TRIUMF’s Life Sciences division. Dr. Schaffer came to TRIUMF in 2009 from the private sector where he worked at General Electric in upstate New York. He earned his Ph.D. in chemistry from McMaster University in 2003 and earned his B.Sc. with honours in chemistry and biochemistry from the University of British Columbia (UBC) in 1998. He is now also an adjunct professor at Simon Fraser University’s Department of Chemistry and an assistant professor in the Department of Radiology at UBC. The commendations for Schaffer are many but he is most recognized for his earnest sincerity, his positive attitude, and his ability to create teams that produce phenomenal results on short time scales. A master of his subject matter, Schaffer has transformed the TRIUMF nuclear-medicine program by focusing on core competencies, specific outcomes, and connections with industrial and commercial interests.

Want to Join the ARTMS Team?

Reach Out to Us

View Job Openings

Questions? Let us know.